Mohan Viswanathan is a Cardiology physician affiliated with Stanford University. OpenAlex indexes 163 publications with 8,055 citations (h-index 39); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 26 Apr 2024.
Clinical trials
- INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study
Sponsor: Emory University
- A Randomized Trial of Diabetes Prevention Through Lifestyle Change in India
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20259 payments
- Abbott LaboratoriesProgram year202514 payments
- Biosense Webster, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
60.8%Beta blocker35.2%Metoprolol Succinate67%Sotalol16%Metoprolol Tartrate9%Carvedilol7%Part D<11 patientsAntiarrhythmic20.5%Amiodarone Hcl28%Flecainide Acetate25%Dofetilide24%Mexiletine Hcl23%Part D<11 patients+ 1 more class in this area
Blood & clotting
33.8%Factor Xa inhibitor33.8%Eliquis80%Xarelto20%Part D≥55 patientsMetabolism & gastrointestinal
5.3%Proton pump inhibitor5.3%Pantoprazole Sodium100%Part D≥35 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Venous Vascular Closure System Versus Manual Compression Following Multiple Access Electrophysiology Procedures
JACC. Clinical electrophysiology
2019 - Clinical Implications of Ablation of Drivers for Atrial Fibrillation
Circulation Arrhythmia and Electrophysiology
2018 - Identification and Characterization of Sites Where Persistent Atrial Fibrillation Is Terminated by Localized Ablation
Circulation Arrhythmia and Electrophysiology
2018 - Radiation Safety in Children With Congenital and Acquired Heart Disease
JACC. Cardiovascular imaging
2017 - Electrical Integration of Human Embryonic Stem Cell-Derived Cardiomyocytes in a Guinea Pig Chronic Infarct Model
Journal of Cardiovascular Pharmacology and Therapeutics
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Renumathy Dhanasekaran, MD, PhD
Stanford University
Euan Ashley, MD
Stanford University
Sarah Donaldson, MD
Stanford University
Peter Fitzgerald, MD
Stanford University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”